Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor–positive breast cancer
Colt A. Egelston, Weihua Guo, Jiayi Tan, Christian Avalos, Diana L. Simons, Min Hui Lim, Yinghui J. Huang, Michael S. Nelson, Arnab Chowdhury, Daniel B. Schmolze, John H. Yim, Laura Kruper, Laleh Melstrom, Kim Margolin, Joanne E. Mortimer, Yuan Yuan, James R. Waisman, Peter P. Lee
Colt A. Egelston, Weihua Guo, Jiayi Tan, Christian Avalos, Diana L. Simons, Min Hui Lim, Yinghui J. Huang, Michael S. Nelson, Arnab Chowdhury, Daniel B. Schmolze, John H. Yim, Laura Kruper, Laleh Melstrom, Kim Margolin, Joanne E. Mortimer, Yuan Yuan, James R. Waisman, Peter P. Lee
View: Text | PDF
Research Article Immunology Oncology

Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor–positive breast cancer

  • Text
  • PDF
Abstract

CD8+ tumor-infiltrating lymphocytes (TILs) are associated with improved survival in triple-negative breast cancer (TNBC) yet have no association with survival in estrogen receptor–positive (ER+) BC. The basis for these contrasting findings remains elusive. We identified subsets of BC tumors infiltrated by CD8+ T cells with characteristic features of exhausted T cells (TEX). Tumors with abundant CD8+ TEX exhibited a distinct tumor microenvironment marked by amplified interferon-γ signaling–related pathways and higher programmed death ligand 1 expression. Paradoxically, higher levels of tumor-infiltrating CD8+ TEX associated with decreased overall survival of patients with ER+ BC but not patients with TNBC. Moreover, high tumor expression of a CD8+ TEX signature identified dramatically reduced survival in premenopausal, but not postmenopausal, patients with ER+ BC. Finally, we demonstrated the value of a tumor TEX signature score in identifying high-risk premenopausal ER+ BC patients among those with intermediate Oncotype DX Breast Recurrence Scores. Our data highlight the complex relationship between CD8+ TILs, interferon-γ signaling, and ER status in BC patient survival. This work identifies tumor-infiltrating CD8+ TEX as a key feature of reduced survival outcomes in premenopausal patients with early-stage ER+ BC.

Authors

Colt A. Egelston, Weihua Guo, Jiayi Tan, Christian Avalos, Diana L. Simons, Min Hui Lim, Yinghui J. Huang, Michael S. Nelson, Arnab Chowdhury, Daniel B. Schmolze, John H. Yim, Laura Kruper, Laleh Melstrom, Kim Margolin, Joanne E. Mortimer, Yuan Yuan, James R. Waisman, Peter P. Lee

×

Figure 4

Altered immune TME in TEXhi breast tumors.

Options: View larger image (or click on image) Download as PowerPoint
Altered immune TME in TEXhi breast tumors.
ER+ breast tumors defined as ...
ER+ breast tumors defined as TEXhi (top 50%) or TEXlo (bottom 50%) by flow cytometry were assayed by immunohistochemistry (IHC) for CD8+ T cell infiltration (teal), CD20+ B cell infiltration (purple), and PD-L1 expression (brown). (A) Representative high-power fields (original magnification, 20×; scale bar: 50 μm). Clinical pathologist scoring for (B) CD8, (C) CD20, and (D) PD-L1 (TEXhi n = 18, TEXlo n = 18; unpaired Student’s t test). TME features of ER+ breast tumors were assessed by NanoString PanCancer Immune transcriptional profiling (n = 36). (E) Absolute abundance of cell type scores and (F) inflammation-related gene expression are displayed as heatmaps normalized across all tissues by cell type or gene (row). Tumor tissues (columns) are annotated by FACS TEX frequency of CD8+ TILs normalized to %CD8 by IHC (%TEX; red), IHC CD8+ T cell infiltration score (%CD8; blue), and IHC PD-L1 expression score (%PD-L1; brown). (G) Top 30 genes differentially expressed (uncorrected Student’s t test P < 0.01) between TEXhi and TEXlo tumors are shown. (H) CIBERSORTx analysis of relative immune populations in TEXhi (top 25%, n = 275) and TEXlo (bottom 25%, n = 275) ER+ breast tumors in METABRIC database. Statistics generated by Wilcoxon’s rank-sum test. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts